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Consideration of Cosegregation in the
Pathogenicity Classification of Genomic Variants
Gail P. Jarvik1,* and Brian L. Browning1
The American College of Medical Genetics and Genomics (ACMG) and Association of Molecular Pathology (AMP) recently published
important new guidelines aiming to improve and standardize the pathogenicity classification of genomic variants. The Clinical
Sequencing Exploratory Research (CSER) consortium evaluated the use of these guidelines across nine laboratories. One identified
obstacle to consistent usage of the ACMG-AMP guidelines is the lack of a definition of cosegregation as criteria for pathogenicity
classification. Cosegregation data differ from many other types of pathogenicity data in being quantitative. However, the ACMG-
AMP guidelines do not define quantitative criteria for use of these data. Here, such quantitative criteria, in an easily implementable
form, are proposed.Introduction
The consideration of cosegregation of a genetic variant and
disease is important data when evaluating the pathoge-
nicity of a genomic variant. Thus, cosegregation is
included as part of the recently published, important
American College of Medical Genetics and Genomics
(ACMG) and Association of Molecular Pathology (AMP)
guidelines aiming to improve and standardize the pathoge-
nicity classification of genomic variants.1 Such guidance is
a crucial step in advancing a consistent implementation of
genomic medicine.
The ACMG-AMP pathogenicity classification guidelines
offer a set of categories that can each be used to offer vary-
ing levels of support for classification of a variant as
benign, likely benign, variant of uncertain significance,
likely pathogenic, or pathogenic. These categories are sum-
marized in the left column of Figure 1. In considering cose-
gregation evidence, non-segregation was considered
strong evidence of a benign variant. Cosegregation with
disease in multiple affected family members was consid-
ered supporting evidence of pathogenicity, and increased
segregation data was considered moderate or strong evi-
dence of pathogenicity. However, non-segregation, segre-
gation, and increased segregation were not quantitatively
defined. The AMCG-AMP guidelines cite the work of
Thompson et al.2 and its extension by Bayrak-Toydemir
et al.,3 but these authors do not propose specific evidence
cutoffs for pathogenicity. Bayrak-Toydemir et al.3 do pro-
pose a so-called Bayes factor (BF) method that computes
a likelihood ratio for quantitation of evidence, and they
discuss the need for a threshold for calling a variant delete-
rious. In this issue of the American Journal of Human
Genetics, the Clinical Sequencing Exploratory Research
(CSER) consortium4 identifies the lack of quantitative
guidelines for cosegregation as a source of discordance in
the implementation of the ACMG-AMP guidelines across
laboratories.51Division of Medical Genetics, Department of Medicine and Department of G
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mented, quantitative guidelines for the consideration of
cosegregation of a variant and a disease in the classification
of variant pathogenicity. These proposed guidelines sup-
port specific ACMG-AMP evidence levels. These guidelines
are designed to be implementable by molecular patholo-
gists and clinical geneticists without advanced statistical
genetics training.Material and Methods
Although the Thompson-Bayrak-Toydemir BFmethod can achieve
more precision when penetrance is incomplete and can be esti-
mated, it is not easily computable by most laboratory personnel
or clinicians. However, if the BFmethod is implemented computa-
tionally in a lab, the thresholds proposed here can be used for that
method as well as the simpler method outlined here.
We calculate a simple probability that the observed variant-
affected status data occur by chance, rather than due to cosegrega-
tion. We assume that the proband(s) have that variant and full
penetrance and that the allele is rare enough that all occurrences
in the observed pedigrees are identical by descent, rather
than the same variant entering the pedigree from more than
one ancestor. Under a dominant model, this probability is
N ¼ ð1=2Þm, where m is the number of meioses of the variant of
interest that are informative for cosegregation.
For example, if the only data are that an affected proband and
one affected parent both carry the variant of interest for a domi-
nant disorder, given that the proband carries the variant, the prob-
ability of the affected parent also carrying it is ð1=2Þ1 ¼ 1=2,
because a singlemeioses informative for cosegregation is observed.
It is important to note that absence of the variant of interest in an
unaffected individual is cosegregation information. Informative
meioses can be totaled across families. If some pedigree members
are not phenotyped or genotyped, the probability of transmission
of a variant can vary from 1/2. The probability for such individuals
is multiplied by the probability for the other cosegregation events
in the family to determine the final probability, given that these
are independent events; this is demonstrated in Figure 2, family 3.enome Sciences, The University of Washington, Seattle, WA 98195, USA
an Journal of Human Genetics 98, 1077–1081, June 2, 2016 1077
Figure 1. ACMG-AMP Pathogenicity Classification Guidelines Updated to Include Cosegregation
The summary table of evidence categories and levels from the ACMG-AMP pathogenicity classification guideline paper by Richards
et al.1 is shown and is updated to include the proposed cosegregation thresholds as outlined in Table 1. The strongest evidence level
supported by a given N is selected. Figure adapted with permission from Richards et al.1This method can be extended to uncertain phenotypes by
weighting the probability of being affected (Figure 2, family 3).
Similarly, this method can be extended to disorders with incom-
plete penetrance by considering the cosegregation in affected
individuals only, although information is lost, or a penetrance
estimate can be added to the calculation.
Our method is more intuitive to many, but under our assump-
tions of complete penetrance, a single causal allele, and no pheno-
copies, N ¼ 1/BF as BF is defined by Thompson.2 Under these
assumptions, the numerator of the BF equation is 1.0 (due to
the complete penetrance) and the denominator is ð1=2Þm. Thus,
N ¼ 1/BF given simplifying assumptions.
Multiple families are jointly considered by adding the informa-
tive meioses across families to obtainm. Thus, if one observes four
pedigrees for which the only data are that the affected child and
affected parent share the same variant of interest in a dominant
disorder, given that the proband in each family has the same
variant, N ¼ (1/2)4. Alternatively, when not all probabilities are
1/2, one multiplies the probability of the independent cosegrega-
tion events in each family together for a final probability.
Large pedigrees are less-often available for recessive disorders;
however, similar calculations can be made. For example, for two
affected siblings who carry the same two variants, the probability
that the proband carries both variants of interest is 1 and N ¼ 1/4;
if three affected siblings share the same affected variant, N ¼ 1/16.
Information from unaffected pedigree members can also be1078 The American Journal of Human Genetics 98, 1077–1081, Juneconsidered. Cosegregation of X-linked disorders can be evaluated
similarly, by setting the probability of the proband carrying the
variant of interest as 1 and evaluating the probability of the
observed cosegregation. For example, N ¼ 1/2 when an affected
male proband has either one affected brother with the variant of
interest or, conversely, one unaffected brother without that
variant.Assigning ACMG-AMP Pathogenicity Evidence Level
The ACMG-AMP guideline paper2 suggests that increasing
amounts of cosegregation evidence could lead to an evidence cri-
terion of supporting evidence, moderate evidence, or strong evi-
dence that a variant is pathogenic. Non-segregation is considered
strong evidence that the variant is benign.
We propose the cutoffs summarized in Table 1 to define the sup-
porting, moderate, and strong evidence levels. Inherent in our sys-
tem is that including data for an individual very often changes the
likelihood, N, by a factor of 1/2, so that these thresholds are mul-
tiples of 1/2. We propose that N be required to be smaller if all the
segregation evidence comes from a single family, rather than two
or more families, solely due to the concern that evidence from a
single family can be due to physical linkage between the observed
variant and an unobserved causal variant.
Given the well-accepted criteria for rejecting the null hypothe-
sis of p% 0.05 and the limitation of segregation data to factors of2, 2016
No ACMG evidence
Figure 2. Examples of Computation of
Cosegregation Evidence
These examples demonstrate the computa-
tion of N proposed here and contrast it
to BF as computed by Bayrak-Toydemir
et al., considering pedigrees from their
paper.3 Filled-in pedigree members are
affected, and hashed are highly suspicious
for the phenotype. A positive sign indi-
cates that the individual harbors the
variant of interest, and a negative sign in-
dicates that the individual was genotyped
and does not harbor the variant of interest.
The proband is identified with an arrow.
Pedigrees reprinted with permission from
Bayrak-Toydemir et al.31/2, N ¼ 1/32 or 1/16 are reasonable levels for strong evidence of
segregation. We propose that the 1/32 criteria be used if all cose-
gregation data come from one pedigree and 1/16 be used if at
least two pedigrees have evidence supporting cosegregation
(Table 1). We continue this dichotomy throughout all evidence
levels.
Once the most restrictive threshold of N ¼ 1/32 is met, further
data need not be considered because the ACMG-AMP guidelines
do not allow segregation data alone to lead to the determination
of very strong evidence of pathogenicity.Nonsegregation
In the case of a fully penetrant disorder, a single unaffected indi-
vidual who has the variant of interest is evidence of nonsegrega-
tion. In our experience these negative data are rarely published,
and evidence databases such as ClinVar6 do not often give nonseg-
regation details sufficient for a calculation. Nonsegregation can be
difficult to access when penetrance is age dependent or incom-
plete and when the variant can enter the pedigree from more
than one source. In that case, consideration of affected individuals
only is conservative. However, for more common diseases the
concern of phenocopies is relevant. For example, a probandThe American Journal of Human Gwith a pathogenic BRCA1 variant might
not share this variant with a sister who
also has breast cancer. Is this evidence
that the variant is not pathogenic or does
the sister have breast cancer from another
cause or sporadic breast cancer? When in-
heritance is complex or when diseases are
common and of heterogeneous etiology,
the conclusion that nonsegregation sup-
ports a benign variant call should be
made with caution.
Results
Examples of Calculating N and
Evidence Level
Examples of computation of N for a
dominant disorder are shown in
Figure 2. These pedigrees were pub-
lished by Bayrak-Toydemir et al.,3
and we use them here to contrasttheir computed BF with N computed here. We have or-
dered them by simplicity of computation, rather than
the family number. Note that in each example, N is a
reasonable approximation of 1/BF. Differences might be
due to the consideration of minor-allele frequency (MAF)
in each case, differences in assumed penetrance and phe-
nocopy rates, and difference in weighting the highly suspi-
cious for affected individuals in family 3.
InFigure2, theparentsof family8donothavegeneticdata
and three affected siblings share the same variant. Because
we assume that the variant of interest occurs in the proband,
there are two additionalmeioses, to the siblings, to consider.
Thus, N ¼ (1/2)2 ¼ 1/4. Note that it is not 1/8 because the
probability that the proband has the variant is assumed to
be 1. The ACMG-AMP evidence level for these data does
not meet the 1/8 single family threshold for ‘‘pathogenic
supporting’’ and is not used in variant classification.
In Figure 2, family 4, the assumption that a very rare
variant does not enter the pedigree from two independent
sources allows us to assume that the untyped relatives
connecting those who carry the variant of interest areenetics 98, 1077–1081, June 2, 2016 1079
Table 1. Proposed Cosegregation Evidence to Support Each
ACMG-AMP1 Pathogenicity Evidence Level
Single Family >1 Family
Strong evidence %1/32 (%0.03) %1/16 (%0.06)
Moderate evidence %1/16 (%0.06) %1/8 (%0.125)
Supporting evidence %1/8 (%0.125) %1/4 (%0.25)
N, probability of observed cosegregation if not pathogenic, totaled over all
families (or 1/BF). Note that the strongest evidence level supported by a given
N is selected.also carriers. The probability of these data given indepen-
dent assortment of the variant and disorder and that the
proband carries the variant is N ¼ (1/2)6. These data yield
an ACMG-AMP evidence level of pathogenic strong, en-
coded as PS.
Figure 2, family 3 adds data on unaffected individuals
and challenges us to consider how to incorporate data
on individuals that probably, but not definitely, have
the disease. Again, we assume that the proband has the
variant and that the variant is so rare that it only enters
the pedigree once; thus, untyped relatives who must
have passed the variant are assumed to have the variant.
Considering definitely affected individuals, we observe
four meioses, so that the affected individuals contribute
a factor of (1/2)4 to the value of N. The probability that
an individual is a noncarrier is 1 minus the probability
that the individual is a carrier. So individual IV-4 contrib-
utes a factor of ð1 ð1=2ÞÞ ¼ 1=2, and individual IV-5
contributes a factor of ð1 ð1=2Þ2Þ ¼ 3=4. Thus, for family
3, N ¼ ð1=2Þ43 ð1=2Þ3ð3=4Þ ¼ 3=ð27Þ ¼ 3=256ð 1=85Þ,
without consideration of the individuals highly suspi-
cious for disease. These individuals can be incorporated
into the evidence with the BF approach. If the highly
suspicious individuals are assumed to be affected, the
segregation probability of 1/4 can be applied; it could
also be reasonable to alter this based on the confidence
that they are affected (e.g., use 1/3 or 1/2 instead of 1/4
to account for the reduced confidence in their diagnoses).
Regardless of the handling of the highly suspicious indi-
viduals, these data yield an ACMG-AMP evidence level
of pathogenic strong.Discussion
Classification of the pathogenicity of variants will be an
ongoing and important task. The repository ClinVar6 al-
lows public reporting of pathogenicity classification,
including the supporting evidence, of variant-disease
pairs. However, inconsistency in the criteria different
labs use to assess pathogenicity was identified as an
obstacle to genomic medicine. The ACMG-AMP guide-
lines are an important effort to bring consistency to
variant classification. Recent work from the CSER con-
sortium identifies sources of variation in the implementa-
tion of ACMG-AMP guidelines and suggests clarifications1080 The American Journal of Human Genetics 98, 1077–1081, Juneand areas for improved guidance.5 One area of concern
is a lack of standard criteria for cosegregation evidence
to be used to support evidence levels. Given that cosegre-
gation data are by definition quantifiable, we seek to
provide such guidance.
As noted above, our use of the probability of the cosegre-
gation data, given independent segregation of the variant
and the disease, under simplifying assumptions, is equal
to 1/BF, considering BF defined by Thompson et al.2 The
BF can be used to incorporate incomplete penetrance,
age-of-onset functions, and MAF and thus the possibility
that the variant is not identical by descent in all pedigree
members and uncertainty in diagnosis. Although some of
these data will be estimated, they can add precision to
the cosegregation evidence, and the BF can be inverted
to evaluate the ACMG-AMP evidence level supported.
The limitation of the BF computation is that it requires
training and tools not required by the method suggested
here. We note that, for disorders with incomplete pene-
trance, N can be computed considering only the affected
individuals. However, this will lose information available
in a calculation where penetrance-by-age functions are
included.
We have made an effort to align our evidence levels
with other data that ACMG-AMP identify as usable to
support the supporting moderate or strong evidence of
pathogenicity levels (Figure 1).1 A case-control study asso-
ciating a variant with the phenotype is considered strong
evidence. Given that this would customarily require a p
value of 0.05 or less, our suggested criteria for segregation
would yield similar evidence. A de novo ‘‘without
maternity and paternity confirmed’’ would constitute
moderate evidence under ACMG-AMP. The ACMG-AMP
guidelines define supporting evidence of pathogenicity
as ‘‘cosegregation with disease in multiple family mem-
bers.’’ 1 This is aligned with our criterion of N ¼ 1/8 in
a single family.
The authors of the ACMG guidelines raise the concern
that cosegregation of a variant with disease in a family
might be secondary to physical linkage between that
observed variant and the actual pathogenic variant.1
This is often a concern in the identification of new
disease—gene associations, where the gene has not previ-
ously been known to be associated with the disorder. As
linkage regions are often very large in a single family,
due to lack of recombination events, the concern over
false positives due to physical linkage of the observed
variant with the true pathogenic variant, which might
even be in a neighboring gene, are reasonable. However,
in the case of the full-sequence data of a gene known to
be associated with the disorder, the likelihood of failing
to identify the pathogenic change in favor of a marker
in physical linkage is substantially reduced versus that
of a partially sequenced linkage region with multiple
possible associated loci. Further, the ACMG-AMP authors
allow case-control association data as strong support of
pathogenicity, and those results can also occur for a2, 2016
non-pathogenic variant in linkage disequilibrium with an
unobserved pathogenic variant. Nonetheless, we do
penalize the case where the variant only has disease
cosegregation data from a single family by a somewhat
arbitrary factor of 2.
Cosegregation cannot be considered very strong evi-
dence of pathogenicity under the ACMG guidelines.1
Under the ACMG-AMP guidelines, the only evidence
considered very strong evidence of pathogenicity is a
nonsense mutation in a gene where nonsense mutations
are a known cause of the disease. Even this is not consid-
ered strong enough stand-alone evidence to call the
variant as pathogenic. Classifying a variant as pathogenic
can occur when one very strong evidence of pathogenicity
is combined with at least one strong support evidence level
or two moderates, or a combination of lesser evidence
levels. For this reason, it seems that the authors of the
ACMG-AMP statement might reconsider whether there is
a level of cosegregation which constitutes very strong
evidence.
We propose here easily quantified criteria for cosegrega-
tion to support evidence levels defined by the ACMG-
AMP variant classification guidelines1 in an effort to
improve standardization of variant classification among
clinical and other genomic laboratories. This is accompa-
nied by a simplified calculation of N and also the ability
to use these guidelines with fewer assumptions by calcula-
tion of a BF2,3 and comparing 1/BF to the cutoffs
proposed.
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